Moderna’s COVID-19 Vaccine Candidate: Phase 3 study met statistical criteria with a vaccine efficacy of 94.5%
BioTech: Memo Therapeutics AG Raises CHF 14 Million in a Series B Financing Round led by Swisscanto Invest by Zürcher Kantonalbank
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2
BioTech: BioNTech to Receive up to €375M in Funding from German Federal Ministry of Education and Research to Support COVID-19 Vaccine